• Founded: 2015
  • CEO: Kevin Eisenfrats
  • Size of Facility: 4600 sq ft
  • Company Size: 8
  • Funding Source: Grants (e.g. SBIR, CRCF, CIT), Investor Funded, Venture Captital/Private Equity
  • Development Stage: Pre-clinical

Contraline is an early-stage biotechnology company developing the first long-lasting, non-hormonal, and reversible form of male birth control. Our first product, Echo-V, is a polymer gel that is implanted non-surgically into the vas deferens via a novel medical procedure called Vasintomy. We conduct research and development in our laboratory in Charlottesville, VA and in partnership with academic institutions, including the University of Virginia.